Navigation Links
3SBio Inc. Announces Second Quarter 2008 Results
Date:8/12/2008

SHENYANG, China, Aug. 12 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter ended June 30, 2008.

Second Quarter 2008 Financial Highlights:

-- Total net revenues increased 38.4% over the second quarter 2007 to

RMB59.6 million (US$8.7 million).

-- Net revenue from our flagship recombinant human erythropoietin

("EPO") products, marketed under our EPIAO brand, increased 23.7%

over the second quarter 2007 to RMB37.1 million (US$5.4 million).

-- Net revenue from our protein-based therapeutic recombinant human

thrombopoietin ("TPO") products, marketed under our TPIAO brand,

increased 66.9% over the second quarter 2007 to RMB16.1 million (US$2.3

million).

-- Operating income increased 10.5% over the second quarter 2007 to

RMB15.2 million (US$2.2 million).

-- Net income decreased 16.9% over the second quarter 2007 to RMB19.4

million (US$2.8 million).

-- Net income per American depositary share ("ADS") for the second

quarter 2008 was RMB0.89 (US$0.13) compared with RMB1.07 for the second

quarter 2007.

First Half 2008 Financial Highlights:

-- Total net revenues increased 46.7% over the first half of 2007 to

RMB115.0 million (US$16.8 million).

-- Net revenue from EPIAO increased 31.7% over the first half of 2007 to

RMB72.6 million (US$10.6 million).

-- Net revenue from TPIAO increased 83.2% over the first half of 2007 to

RMB31.5 million (US$4.6 milli
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... LONDON , December 23, 2014 ... Review Algeria , out today and available for free ... the actors driving change and growth in the sector today. ... has scored notable successes has been in developing a homegrown ... 70 percent local production still remains some way off. A ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... , , SEATTLE and ATLANTA, ... it has signed a lease agreement with Majestic Realty Co. to build ... to manufacture PROVENGE(R) (sipuleucel-T) for patients with advanced prostate cancer. The ... , , If approved by the U.S. Food and ...
... , , , , ... results for its first fiscal quarter ended June 30, 2009. Net sales increased 22% ... year. , , Net loss for the quarter was ... of the prior fiscal year of $587,000 or $0.05 per share. The prior ...
... BOZEN, Italy, August 10 , ... Robotics , Health Robotics today announced ... for Health Robotics, CytoCare Robot. The,agreement enables McKesson to achieve ... Oncology I.V. admixtures. , "We are ...
Cached Biology Technology:Dendreon Signs Lease for New Manufacturing Facility in Atlanta 2Dendreon Signs Lease for New Manufacturing Facility in Atlanta 3Imagenetix, Inc. Reports First Quarter 2010 Results 2Imagenetix, Inc. Reports First Quarter 2010 Results 3Imagenetix, Inc. Reports First Quarter 2010 Results 4Imagenetix, Inc. Reports First Quarter 2010 Results 5McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Researchers with the UC Davis MIND Institute and Agilent ... disorder best known for causing an insatiable appetite that ... the loss of non-coding RNAs, resulting in the dysregulation ... metabolic differences during sleep. The research was led ...
... YORK, NY (June 25, 2013) Researchers at Columbia ... called caspase-2 is a key regulator of a signaling ... The findings, made in a mouse model of Alzheimer,s, ... damage and subsequent cognitive decline associated with the disease. ...
... added another piece to the evolutionary puzzle to explain why ... remained tiny. In research published in Proceedings of ... including Monash University,s Dr Alistair Evans proposed a new theory ... shrew which weighs around two grams, to the blue whale ...
Cached Biology News:Symptoms of Prader-Willi syndrome associated with interference in circadian, metabolic genes 2Study identifies protein that contributes to cognitive decline in Alzheimer's 2From minute to massive -- mammal size evolution explained 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: